|
Search
Search through the thousands of lawsuits, complaints and recalls on our site.
|
ETHEX Corporation Voluntarily Recalls a Single Lot of Morphine Sulfate 60 mg Extended Release Tablets Due to the Potential for Oversized TabletsDate: 6/12/2008
Reason: Oversized tablets may contain as much as two times the labeled level of active morphine sulfate
The Food and Drug Administration (FDA) released the following information:
ETHEX Corporation Voluntarily Recalls a Single Lot of Morphine Sulfate 60 mg Extended Release Tablets Due to the Potential for Oversized TabletsContact: FOR IMMEDIATE RELEASE -- St. Louis, MO – June 9, 2008 – ETHEX Corporation announced today that it has voluntarily recalled a single lot of morphine sulfate 60 mg extended release tablets (Lot No. 91762) due to a report of a tablet with twice the appropriate thickness. Oversized tablets may contain as much as two times the labeled level of active morphine sulfate. The lot was distributed by ETHEX Corporation under an "ETHEX" label between April 16th and April 27th of 2008. No other dosage strength, nor any other lot of the 60 mg strength is affected by this recall. The voluntary single-lot recall is due to a report that a tablet with as much as double the appropriate thickness was identified and the possibility therefore that there may be other similar oversized tablets that may have been commercially released in the affected lot. Such tablets may contain as much as twice the labeled level of active morphine ingredient. The product is a white oval tablet with "60" on one side, and "E" on the reverse. No report of unexpected side effects or injury has been received. However, opioids such as morphine have life-threatening consequences if overdosed. Those consequences can include respiratory depression (difficulty or lack of breathing), and low blood pressure. Many patients for whom this product is prescribed are likely to be highly debilitated with reduced strength or energy as a result of illness. As such, they may be less likely to be able to determine that a tablet is overweight or oversized than an unimpaired individual. Any customer inquiries related to this action should be addressed to ETHEX Customer Service at 1-800-321-1705, or fax to ETHEX Customer Service at 314-646-3751 or sent via email to: customer-service@ethex.com with representatives available Monday through Friday, 8 am to 5 pm CST. ETHEX Corporation previously initiated the recall notification to wholesalers and retailers who have received any inventory of the recalled lot of this product with instructions for returning the recalled product and, if they have not already done so, they are urged to contact the number above regarding procedures for returning the recalled product. If consumers have any questions about the recall, they should call the number above, their physician, their pharmacist or other health care provider. This recall is being conducted with the knowledge of the Food and Drug Administration (FDA). Other Drugs / Medicines Recalls and Alerts of InterestDate: 7/15/2008 Reason: Jack Distribution, LLC, is conducting this recall after being informed by representatives of the Food and Drug Administration (FDA) that lab analysis by FDA of Rize 2 and Rose 4 Her samples from lots manufactured and packaged in 2007 found the product contains potentially harmful, undeclared ingredients. Distribution: Nationwide Date: 7/16/2008 Reason: A sample from product lot 856396A tested positive for a strain of yeast, which could potentially affect immunocompromised patients. Distribution: Nationwide Date: 7/15/2008 Reason: As a precautionary measure, Sage Products announced a voluntary recall of limited lots of 2% Chlorhexidine Gluconate (CHG) Cloth Patient Preoperative Skin Preparation product. Distribution: Nationwide Date: 6/12/2008 Reason: Taking AZASAN® instead of SOLODYN® presents a health hazard and safety risk to patients Date: 6/16/2008 Reason: Oversized tablets may contain as much as two times the labeled level of active morphine sulfate Distribution: Nationwide Date: 6/12/2008 Reason: it contained a potentially harmful undeclared ingredient, hydroxyhomosildenafil Distribution: Nationwide |
|
© 2000 - 2008 Copyright. All rights reserved nola3, llc.








